Clinical Trial Update: Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 study evaluating anti-CD19 CAR NK cells in relapsed and refractory B-cell lymphoma. The current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Anti-CD19 CAR-NK cells (Chimeric Antigen Receptor NK cell therapy targeting CD19)

Snippet

Sponsor: Allife Medical Science and Technology Co., Ltd. | Conditions: Refractory B-Cell Lymphoma | EARLY_Phase 1 | Status: UNKNOWN